This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
COAST
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD).
Overview
A 2-year Phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study.
Primary efficacy will be determined at Week 52.
For further information about this study please contact the Cerulea on +61 3 8638 5300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Dr Thanh Nguyen
A 2-year Phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study.
Primary efficacy will be determined at Week 52.
For further information about this study please contact the Cerulea on +61 3 8638 5300 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.